- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04380467
Vitamin D Supplementation in CKD - Vascular Function, Structure and Immune Regulation
Impact of Vitamin D Supplementation on Vascular Function, Vascular Structure and Immune Regulation in Patients With Chronic Kidney Disease and Low Vitamin D Levels - A Pilot Randomised Trial
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The study is a single (observer) blinded feasibility pilot randomised study. Study subjects will be recruited from clinics run by St George's Hospital Renal Department and randomised to treatment arm or no treatment arm.
In treatment arm, six doses of vitamin D tablets (cholecalciferol 100,000 IU, five capsules total) will be administered on weeks 0, 4, 8, 12, 16 and 20. In the no-treatment arm the participants receive no cholecalciferol. Participants will have serum calcium levels measured at week 12.
All participants will undergo estimation of endothelial function, carotid intima-media thickness, CD4+CD28null and regulatory T cell frequency in week 0 and week 26. The observer will be blinded to whether the patient is in the treatment or no-treatment arm whilst the following tests are performed:
- Measurement of Brachial Artery Flow Mediated Dilatation
- Measurement of Carotid Intima Media Thickness
- Quantification of CD4+CD28null and regulatory T cell frequency
The pilot study will assess feasibility of the study methods.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Tooting
-
London, Tooting, Det Forenede Kongerige, sw17 0QT
- Debasish Banerjee
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age 18-80 years
- Calcium < 2.58mmol/l
- On an ACE inhibitor/ARB
- Vitamin D <75nmol/l
- eGFR 15- 60ml/min/1.73m2 and stable
- Informed consent to participate
Exclusion Criteria:
- Patients already on Vitamin D or calcium supplementation
- Patients with known malignancies
- Patients with autoimmune conditions
- Patients with heart failure (ejection fraction <40%, Plasma NT pro-BNP>500pg/ml)
- Patients with active infection
- Rapidly deteriorating renal function
- Recent Acute coronary syndrome or cerebro-vascular event (within the last 6 months)
- Uncontrolled hypertension (BP>160 systolic)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Vitamin D Group
Six doses of cholecalciferol 100,000units (5x aviticol 20,000units capsules) administered monthly over 20 weeks.
|
(aviticol) 5x 20,000unit capsules administered monthly over 20 weeks
|
|
Ingen indgriben: Control
No vitamin D given
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Recruitment rate
Tidsramme: 3 months
|
Percentage of patients recruited from those eligible for the study.
|
3 months
|
|
Retention rate
Tidsramme: 6 months
|
Percentage of patients recruited who completed the follow up investigations
|
6 months
|
|
Acceptability to patients of randomisation procedures
Tidsramme: 6 months
|
Acceptability as assessed by quantitative and qualitative analysis of Participant Experience Survey
|
6 months
|
|
Randomisation procedure
Tidsramme: 6 months
|
Comparison of baseline indices of two patient groups
|
6 months
|
|
Maintenance of single (observer) blinding
Tidsramme: 6 months
|
Incidences of unblinding of study investigator
|
6 months
|
|
Adherence to vitamin D supplementation
Tidsramme: 6 months
|
Subjective adherence as assessed by Participant Experience Survey and biochemical correlation by comparison of follow up vitamin D levels
|
6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Witnessed change in FMD between treated and untreated subjects
Tidsramme: 6 months
|
Flow Mediated Dilatation
|
6 months
|
|
Witnessed change in CIMT between treated and untreated subjects
Tidsramme: 6 months
|
Carotid Intima Media Thickness
|
6 months
|
|
Witnessed change in T lymphocyte subset frequency between treated and untreated subjects
Tidsramme: 6 months
|
CD4+CD28null T lymphocytes and Regulatory T cells as determined by flow cytometry of whole blood
|
6 months
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Debasish Banarjee, St Georges University NHS Foundation Trust
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Hjerte-kar-sygdomme
- Karsygdomme
- Åreforkalkning
- Arterielle okklusive sygdomme
- Urologiske sygdomme
- Nyreinsufficiens
- Nyresygdomme
- Nyreinsufficiens, kronisk
- Åreforkalkning
- Lægemidlers fysiologiske virkninger
- Mikronæringsstoffer
- Vitaminer
- Knogletæthedsbevarende midler
- Calciumregulerende hormoner og midler
- D-vitamin
- Cholecalciferol
Andre undersøgelses-id-numre
- 15.0236
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .